Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Michael Heltzen is Chief Executive Officer at Exozymes. OQRO lists 10 transactions filed with the SEC under this name, the latest on Sep 2, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
10
Companies involved
1
1 buy, median +34.4 pts vs S&P 500, beat it 1 of 1 time.
Average +34.4 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jul 2, 2025 to Jul 2, 2025, measured from the first close after the filing. Past results, not a forecast.
4 purchases disclosed; 100% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $563 today ($1K put in); the same in the S&P 500 (SPY): $976.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
ExozymesEXOZ
10 disclosures · Nov 2024 – Sep 2026 · 9 bought
Aug 26, 2026Bought~$1.8Kdisclosed Sep 2
DetailsOfficial recordAug 26, 2026Bought~$1.9Kdisclosed Sep 2
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aug 25, 2026Bought~$1.9Kdisclosed Sep 2
DetailsOfficial recordAug 25, 2026Bought~$750disclosed Sep 2
DetailsOfficial recordAug 26, 2026Bought~$30disclosed Sep 2
DetailsOfficial recordAug 19, 20268,841disclosed Sep 2
DetailsOfficial recordJul 2, 2025Bought~$11K
DetailsOfficial recordJan 17, 2025Bought~$19Kdisclosed Jan 21
DetailsOfficial recordJan 16, 2025Bought~$1.3Kdisclosed Jan 21
DetailsOfficial recordNov 15, 2024Bought~$22Kdisclosed Nov 19
DetailsOfficial recordAs of the latest filing on , Michael Heltzen reported holding 14,453 shares of Exozymes (EXOZ), worth about $55K at the last close of $4 (Nov 13, 2026). In the last 12 months, Michael Heltzen bought $6.4K in 5 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Exozymes EXOZ | 14,453 | 14K direct | $4 | $55K | Aug 26, 2026 |
Is this Michael Heltzen’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Michael Heltzen bought shares on the open market in 2024, 2025 and 2026.
Michael Heltzen reported 9 open-market purchases and 0 sales since 2024; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $6.4K5×5 trades | — |
| 2025 | $31K3×3 trades | — |
| 2024 | $22K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Aug 26, 2026, Michael Heltzen reported holding 14,453 shares of Exozymes (EXOZ). At the last close of $4 on Nov 13, 2026, that is about $55K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Michael Heltzen reported 5 open-market purchases worth $6.4K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Michael Heltzen bought shares on the open market in 2024, 2025 and 2026.
In SEC filings since 2024: the latest open-market purchase is from 2026; no open-market sale is on record.
Exozymes (EXOZ), from 2024 to 2026: 9 purchases and 0 sales.
Michael Heltzen reported 9 open-market purchases and 0 sales here, 2024 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.